No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ABBV240719P170000
- 1.80
- -0.60-25.00%
15min DelayTrading Jul 16 10:01 ET
2.65High1.80Low
2.60Open2.40Pre Close4 Volume1.10K Open Interest170.00Strike Price970.00Turnover19.82%IV0.43%PremiumJul 19, 2024Expiry Date1.07Intrinsic Value100Multiplier3DDays to Expiry0.73Extrinsic Value100Contract SizeAmericanOptions Type-0.6370Delta0.1144Gamma87.98Leverage Ratio-0.1710Theta-0.0092Rho-56.05Eff Leverage0.0627Vega
Intraday
- 5D
- Daily
News
AbbVie Invests in Sionna as Part of Licensing Deal for CF Drugs
Express News | Sionna Therapeutics Secures Exclusive Worldwide Rights To Develop And Commercialize AbbVie's CF Compounds ABBV-2222
Express News | Sionna Therapeutics: Abbvie to Get Upfront Payment, Equity Investment in Sionna
Express News | Sionna Therapeutics Expands Pipeline With Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement With Abbvie
SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Diseases | DelveInsight
Ulcerative colitis is an idiopathic inflammatory bowel disease affecting ~1.5 million patients in the US and with an unknown exact cause. It affects...
AbbVie Looks to Add an Eighth Indication for JAK Inhibitor Rinvoq
Comments
$Genmab(GMAB.US$ $AbbVie(ABBV.US$
EPKINLY (Epcoritamab) Now Approved for Patients w/ Follicular Lymphoma (FL)
» Positive results in Ph1/2 EPCORE® NHL-1 study for R/R FL
» Offers off-the-shelf T-cell therapy
» First-of-its-kind antibody for both R/R FL & DLBCL after prior treatments (2+ lines)
EPKINLY (Epcoritamab) Now Approved for Patients w/ Follicular Lymphoma (FL)
» Positive results in Ph1/2 EPCORE® NHL-1 study for R/R FL
» Offers off-the-shelf T-cell therapy
» First-of-its-kind antibody for both R/R FL & DLBCL after prior treatments (2+ lines)
3
$Chevron(CVX.US$
One of the U.S.’s largest energy corporations, Chevron Corporation (NYSE:CVX) specializes in oil, gas and renewable fuels. The company has upstream and downstream operations focused on the oil and gas industry. Oil companies are an interesting pick since the best ones are known for paying dividends, even in bad times.
Chevron has a 37-year history of increasing dividends and has consistently paid them since ...
One of the U.S.’s largest energy corporations, Chevron Corporation (NYSE:CVX) specializes in oil, gas and renewable fuels. The company has upstream and downstream operations focused on the oil and gas industry. Oil companies are an interesting pick since the best ones are known for paying dividends, even in bad times.
Chevron has a 37-year history of increasing dividends and has consistently paid them since ...
33
3
From YouTube
6
Interesting both for the (1) shift in the macro-trend to M&A (vs. Licensing) and (2) change in top spenders
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
10
1
Read more